Pathobiology of pulmonary hypertension. Extracellular matrix

M Rabinovitch

doi:10.1016/s0272-5231(05)70282-3

Pathobiology of pulmonary hypertension. Extracellular matrix

Clin Chest Med. 2001 Sep;22(3):433-49, viii. doi: 10.1016/s0272-5231(05)70282-3.

Author

M Rabinovitch¹

Affiliation

¹ Departments of Pediatrics, Laboratory Medicine and Pathobiology, and Medicine, University of Toronto, Cardiovascular Research Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada. mr@sickkids.on.ca

PMID: 11590839
DOI: 10.1016/s0272-5231(05)70282-3

Abstract

Changes in the extracellular matrix underlie the structural and functional abnormalities in the vessel wall that lead to progressive pulmonary vascular disease. Studies are reviewed aimed at addressing the cellular and molecular programs that regulate the production of the extracellular matrix describing new ways to arrest proliferation and migration of smooth muscle cells and to induce apoptosis. The latter can lead to the reversal of pathology at least in experimental animal models.

Publication types

Review

MeSH terms

Animals
Endothelium, Vascular / pathology
Endothelium, Vascular / physiology
Extracellular Matrix / pathology*
Fibronectins / metabolism
Fibronectins / physiology
Humans
Hypertension, Pulmonary / enzymology
Hypertension, Pulmonary / pathology*
Hypertension, Pulmonary / physiopathology*
Immunohistochemistry
Inflammation / pathology
Lung / pathology
Muscle, Smooth, Vascular / pathology
Muscle, Smooth, Vascular / physiology
Pancreatic Elastase / metabolism
Pulmonary Artery / pathology
Tenascin / metabolism
Tenascin / physiology

Substances

Fibronectins
Tenascin
Pancreatic Elastase